Halozyme Therapeutics Financial Statements
NASDAQ: HALOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Halozyme Therapeutics revenue and earnings
In fiscal 2025, Halozyme Therapeutics generated $1.40 billion in revenue, up 37.6% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $316.9 million (-28.6% year over year), for a net margin of 22.7% versus a median of 43.7% in the prior 5 years. Gross margin was 83.6% (down from 84.3%) and operating margin 33.6%.
Diluted earnings per share came in at $2.56, down from $3.43. Over the last 5 fiscal years, HALO's revenue has grown at a 39.2% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Halozyme Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.40B | 1.02B | 829.25M | 660.12M | 443.31M | 267.59M | 195.99M | 151.86M | 316.61M | 146.69M |
| Revenue growth (YoY) | +37.55% | +22.44% | +25.62% | +48.91% | +65.67% | +36.53% | +29.06% | -52.04% | +115.84% | +8.61% |
| Cost of Revenue | 228.77M | 159.42M | 192.36M | 139.30M | 81.41M | 43.37M | 45.55M | 10.14M | 31.15M | 33.21M |
| Gross Profit | 1.17B | 855.91M | 636.89M | 520.81M | 361.90M | 224.23M | 150.45M | 141.73M | 285.46M | 113.48M |
| Operating Expenses | 698.83M | 304.43M | 299.32M | 253.28M | 86.00M | 79.97M | 218.06M | 211.06M | 204.46M | 196.69M |
| Research & Development | 81.49M | 79.05M | 76.36M | 66.61M | 35.67M | 34.24M | 140.80M | 150.25M | 150.64M | 150.84M |
| Selling, General & Admin | 207.09M | 154.34M | 149.18M | 143.53M | 50.32M | 45.74M | 77.25M | 60.80M | 53.82M | 45.85M |
| Operating Income | 469.01M | 551.48M | 337.57M | 267.53M | 275.90M | 144.25M | -67.61M | -69.33M | 81.00M | -83.21M |
| Interest Expense | 18.13M | 18.09M | 18.76M | 16.95M | 7.53M | 20.38M | 11.63M | 18.04M | 21.98M | 19.98M |
| Other Income (Expense) | 21.47M | 23.75M | 16.32M | 1.05M | 1.10M | 5.42M | 6.99M | 7.58M | 2.59M | 1.33M |
| Pretax Income | 466.88M | 557.13M | 348.33M | 248.92M | 248.52M | 129.30M | -72.25M | -79.79M | 61.61M | -101.86M |
| Income Tax | 149.99M | 113.04M | 66.73M | 46.79M | -154.19M | 217.00K | -11.00K | 537.00K | -1.36M | 1.16M |
| Net Income | 316.89M | 444.09M | 281.59M | 202.13M | 402.71M | 129.09M | -72.24M | -80.33M | 62.97M | -103.02M |
| Net Income growth (YoY) | -28.64% | +57.71% | +39.31% | -49.81% | +211.97% | — | — | -227.57% | — | — |
| EPS (Basic) | 2.64 | 3.50 | 2.13 | 1.48 | 2.86 | 0.95 | -0.50 | -0.56 | 0.46 | -0.81 |
| EPS (Diluted) | 2.56 | 3.43 | 2.10 | 1.44 | 2.74 | 0.91 | -0.50 | -0.56 | 0.45 | -0.81 |
| Shares Outstanding (Basic) | 119.84M | 126.83M | 131.93M | 136.84M | 140.65M | 136.21M | 144.33M | 143.60M | 136.42M | 127.96M |
| Shares Outstanding (Diluted) | 123.90M | 129.42M | 134.20M | 140.61M | 146.80M | 141.46M | 144.33M | 143.60M | 139.07M | 127.96M |
| EBITDA | 480.39M | 561.74M | 348.66M | 274.02M | 278.90M | 147.54M | -63.54M | -66.94M | 83.16M | -80.80M |
| Gross Margin | 83.62% | 84.30% | 76.80% | 78.90% | 81.64% | 83.79% | 76.76% | 93.33% | 90.16% | 77.36% |
| Operating Margin | 33.58% | 54.32% | 40.71% | 40.53% | 62.24% | 53.91% | -34.50% | -45.65% | 25.58% | -56.72% |
| Net Margin | 22.69% | 43.74% | 33.96% | 30.62% | 90.84% | 48.24% | -36.86% | -52.90% | 19.89% | -70.23% |
This table shows 10 annual periods of Halozyme Therapeutics's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow HALO's reporting calendar. What is a income statement?